Crohn's Disease
Conditions
Brief summary
This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled. The primary endpoints include the incidence rates of adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs) and serious ADRs, as well as the proportion of subjects achieving clinical remission (CDAI score \< 150) at Week 26.
Interventions
Adalimumab is a human anti-tumour necrosis factor-alpha monoclonal antibody that inhibits the downstream inflammatory cascade by blocking TNF-α, a core inflammatory factor in psoriasis.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* The subject must sign the informed consent form. * Aged 18 to 70 years inclusive, no gender restriction. * Subjects with definite diagnosis of Crohn's disease in accordance with Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023), presenting moderate to severe active Crohn's disease with inadequate response, intolerance or contraindication to adequate glucocorticoid and/or immunosuppressant therapy. * Adult patients with Crohn's disease who are prescribed Tabellvi® Adalimumab Injection by physicians following thorough risk-benefit assessment. * Female subjects of childbearing potential must agree to use one contraceptive method approved by the investigator.
Exclusion criteria
* Subjects who are not suitable for treatment with Tabellvi® Adalimumab Injection based on the prescribing information of Tabellvi® Adalimumab Injection and the judgment of the treating physician. * Female subjects who are pregnant or breastfeeding, or who plan to become pregnant during the study period. * Subjects with hypersensitivity to any component of Tabellvi® Adalimumab Injection. * Subjects with active, chronic or recurrent infections, or a medical history of invasive infections (e.g., listeriosis, histoplasmosis). * Subjects with active infections requiring intravenous anti-infective therapy within 30 days prior to the first dose, or those who have received oral anti-infective drugs within 14 days prior to the first dose. * Subjects with active tuberculosis infection; or latent tuberculosis infection without adequate treatment; subjects infected with human immunodeficiency virus (HIV); subjects positive for hepatitis C virus antibody (HCV Ab) indicating previous or current infection; subjects positive for hepatitis B surface antigen (HBsAg), or positive for total hepatitis B core antibody (total Hepatitis B core Ab) with positive hepatitis B virus (HBV)-DNA polymerase chain reaction test result. * Subjects with syphilis infection requiring treatment. * Subjects with moderate to severe heart failure (NYHA Class III/IV), recent cerebrovascular accident, or other medical conditions that may put the subject at risk by participating in this study. * Subjects with current evidence of dysplasia or a history of malignant tumors (including lymphoma and leukemia), except cured non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma or localized cervical carcinoma in situ. * Subjects with a history of demyelinating diseases (including myelitis), or neurological symptoms suggestive of demyelinating diseases. * Subjects who have undergone intestinal resection within the past 6 months, or plan to undergo intestinal resection at any time in the future. * Subjects receiving total parenteral nutrition (TPN), or planning to receive TPN at any time during the study period. * Subjects with an ostomy or an ileal pouch-anal anastomosis (IPAA) pouch. * Subjects with internal or external fistulas, except perianal fistulas without abscess. * Subjects with known symptomatic obstructive intestinal strictures. * Subjects diagnosed with ulcerative colitis or indeterminate colitis. * Subjects with any of the following abnormal laboratory or other examination results during the screening period: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 1.5 times the upper limit of the reference range; white blood cell count \< 3.0×10⁹/L; electrocardiogram (ECG) with clinically significant abnormalities; total bilirubin ≥3 mg/dL (isolated elevated indirect bilirubin caused by Gilbert's syndrome excluded); serum creatinine \>1.6 mg/dL. * Subjects with other clinically significant abnormal laboratory test results (other than those listed above) identified by the investigator during screening. * Subjects who have received other tumor necrosis factor-alpha (TNF-α) inhibitor therapy within 12 weeks before receiving the first dose of Tabellvi® Adalimumab Injection. * Subjects currently participating in another clinical study. * Subjects deemed unsuitable for participation in this trial by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serious Adverse Event (SAE) | Baseline up to 54 weeks | Incidence rate of serious adverse events，the severity will be graded according to the NCI CTCAE Version 6.0 grading scale. |
| Adverse Event (AE) | Baseline up to 54 weeks | Incidence rate of adverse events，the severity will be graded according to the NCI CTCAE Version 6.0 grading scale. |
| Adverse Drug Reaction (ADR) | Baseline up to 54 weeks | Incidence rate of adverse drug reaction，the severity will be graded according to the NCI CTCAE Version 6.0 grading scale. |
| Serious Adverse Drug Reaction | Baseline up to 54 weeks | Incidence rate of serious adverse drug reaction，the severity will be graded according to the NCI CTCAE Version 6.0 grading scale. |
| Clinical remission (CDAI < 150) | At Week 26 post-dose | The proportion of subjects achieving clinical remission (CDAI score\<150) at Week 26 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical remission (CDAI < 150) | At Weeks 4, 12, and 52 post-dose | The proportion of subjects achieving clinical remission (CDAI \< 150) at Weeks 4, 12, and 52 post-dose. |
| Clinical response (reduction in CDAI ≥70 points from baseline) | At Weeks 4, 12, 26 and 52 post-dose | The proportion of subjects achieving clinical response (CDAI reduction ≥70 points from baseline) at Weeks 4, 12, 26, and 52 post-dose. |
| Endoscopic remission | At Week 26 post-dose | The proportion of subjects achieving endoscopic remission at Week 26 post-dose |
| C-reactive protein (CRP) | At Weeks 12, 26, and 52 post-dose | Changes in C-reactive protein (CRP) from baseline at Weeks 12, 26, and 52 post-dose. |
| Fecal calprotectin (FC) | At Weeks 12, 26, and 52 post-dose | Changes in fecal calprotectin (FC) from baseline at Weeks 12, 26, and 52 after administration. |
Countries
China
Contacts
CONTACTJun Shen, Doctor
Outcome results
None listed